Sustained release pharmaceutical composition

Details Sustained release pharmaceutical composition Sustained release pharmaceutical composition

1993-05-28

1997-03-25

Lukton, David

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 12, 530402, 530399, 424488, A61K 3816

Patent

active

056144873

ABSTRACT:
The present document discloses the formation of imine adducts, preferably between a primary amine of a biologically active polypeptide and a reactive aldehyde group of a physiologically acceptable carrier. The imine adduct of human growth hormone and dextran is specifically described. These adducts serve to release the biologically active polypeptide via the reversible reaction in the formation of the imine adduct bond. These adducts have a surprising degree of stability that permits the use of the complex as a sustained release preparation. A key advantage of this technology is that after hydrolysis the complex releases the unmodified pharmaceutical. Thus, these adducts can be used as pharmaceutical compositions useful for the sustained release of the biologically active polypeptide over a predetermined, desired period of time.

REFERENCES:
patent: 3947352 (1976-03-01), Cuatrecasas
patent: 4003792 (1977-01-01), Mill et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4446316 (1984-05-01), Chazov et al.
patent: 4452773 (1984-06-01), Molday
patent: 4585754 (1986-04-01), Meisner et al.
patent: 4745180 (1988-05-01), Moreland et al.
patent: 4857505 (1989-08-01), Arendt
patent: 5130255 (1992-07-01), Battersby et al.
Juliano, R. L., "Drug Delivery Systems, Characteristics and Biomedical Applications", Oxford University Press, New York, pp. 258-312 (1980).
Langer, R. S., et al., "Medical Applications of Controlled Release", CRC Press, Inc., Florida, 1:109 (1984).
Lee, P. I., et al., "Controlled-Release Technology, Pharmaceutical Applications", American Chemical Society Symposium Series 348, Wash. D. C., pp. 188-200 (1987).
Bernstein, A., et al., "Higher Antitumor Efficacy of Daunomycin When Linked To Dextran:In Vivo and In Vitro Studies", J. Natl. Cancer Inst., 60:379 (1978).
Odya, C. E., et al., "Soluble Dextran Complexes of Kallikrein, Bradykinin and Enzyme Inhibitors", Biochemical Pharmacology, 27:173 (1978).
Jentoft, N., et al., "Protein Labeling by Reductive Alkylation", Methods in Enzymology, 91:570 (1983).
Dixon, H. B. F., "N-Terminal Modification of Proteins--A Review", Journal of Protein Chemistry, 3:99 (1984).
Tuma, D. J., et al., "Enhancement of Acetaldehyde-Protein Adduct Formation by L-Ascorbate", Archives of Biochemistry and Biophysics, 234:377 (1984).
Molteni Meth Enz 112, 285, 1985.
Wagner and Zook, Synthetic Organic Chemistry, John Wiley and Sons Inc., N.Y. 1953, p. 728.

Affiliated with

Also associated with

Rating

Sustained release pharmaceutical composition does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Sustained release pharmaceutical composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sustained release pharmaceutical composition will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2203391